Cyclin-dependent kinase-like 1 (CDKL1)

Cyclin-dependent kinase-like 1 (CDKL1) is a member of the CDC2-related serine/threonine protein kinase family, structurally related to cyclin-dependent kinases but evolutionarily distinct, with unique substrate specificity[1][2][3][4][5]. CDKL1 primarily localizes to the nucleus and plays important roles in cell cycle progression, proliferation, survival, and differentiation. It is frequently overexpressed in several cancers, where it contributes to tumor growth and chemoresistance while suppressing apoptosis[1]. In various animal models, CDKL1 is also involved in nervous system development and the regulation of ciliary structure and function, with loss-of-function leading to developmental or neurological defects[2]. CDKL1 dysregulation or altered expression has been associated with cancer, neurodegenerative diseases, and inflammation, and it is under investigation as a biomarker and potential therapeutic target in oncology and neurology[1][4]. No approved drugs specifically target CDKL1 to date.

Other names

KKIALREProtein kinase p42 KKIALRESerine/threonine-protein kinase KKIALREP42CDC2-related kinaseCDKL1_HUMAN

Inhibition of kinase activity (in tumor studies), cell cycle arrest via G0/G1 blocking, induction of apoptosis when silenced